

FDA医薬品安全性コミュニケーション：FDAは、ベンゾジアゼピンまたはCNS抑制剤を服用している患者からオピオイド依存症の薬を差し控えることについて注意を促します：注意深い薬の管理はリスクを減らすことができます

[これにより、FDAの医薬品安全性コミュニケーション\(/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or\)](#)に最新の情報が提供されます。FDAは、オピオイドの痛みや咳止め薬をベンゾジアゼピンと組み合わせると、深刻なリスクと死亡について警告します。2016年8月31日に発行された最強の警告が必要です。[\(/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or\)](#)

安全に関するお知らせ

[2017年9月20日]追加のレビューに基づいて、米国食品医薬品局（FDA）は、中枢神経系を低下させるベンゾジアゼピンまたは他の薬物を服用している患者からオピオイド依存症薬のブプレノルフィンおよびメタドン¹を差し控えるべきではないとアドバイスしています（CNS）。これらの薬を併用すると、深刻な副作用のリスクが高まります。ただし、未治療のオピオイド依存症によって引き起こされる害は、これらのリスクを上回る可能性があります。医療専門家による注意深い投薬管理は、これらのリスクを減らすことができます。この情報をブプレノルフィンとメタドンの薬剤ラベルに追加するとともに、薬物療法（MAT）薬とベンゾジアゼピンの併用を最小限に抑えるための詳細な推奨事項を追加する必要があります。

ブプレノルフィンとメタドンは、処方鎮痛薬やヘロインなどのオピオイドの乱用を減らしたり止めたりするのに役立ちます。メタドンとブプレノルフィンは、オピオイド依存症と依存症に関連する健康への悪影響と死亡を減らすのに効果的であることが示されています。¹これらの薬は、カウンセリングや行動療法と

<https://www.samhsa.gov/medication-assisted-treatment/treatment#counseling-behavioral-therapies>）組み合わせて使用されることが多く、患者は無期限に治療することができます。ブプレノルフィンとメタドンは、患者が依存しているオピオイドと同じ脳の部分に作用することによって機能します。指示通りに薬を服用している患者は、一般的に気分が悪く、離脱は起こりません。ブプレノルフィンとメタドンも渴望を減らすのに役立ちます²（表1を参照してください。ブプレノルフィンおよびメタドンMAT薬のリスト）。

↑
上0

オピオイド依存症の多くの患者は、医療専門家の指示の下で、または不法に、ベンゾジアゼピンまたは他の中枢神経抑制剤を使用することもあります。これらの薬を併用することには重大なリスクがありますが、ベンゾジアゼピンまたはCNS抑制剤の使用により、MATから患者を除外したり、治療から患者を退院させたりしても、これらの薬の併用が妨げられる可能性はありません。代わりに、併用は治療設定の外で継続する可能性があり、それはより深刻な結果をもたらす可能性があります。

ブプレノルフィンまたはメタドンをベンゾジアゼピンまたは他の中枢神経抑制剤と組み合わせて使用する場合、医療専門家はいくつかの行動と予防策を講じ、治療計画を立てる必要があります。これらには以下が含まれます：

- 過剰摂取や死亡など、処方どおりに使用した場合や違法に使用した場合でもCNS抑制剤で発生する可能性のある、併用の深刻なリスクについて患者を教育します。
- MATを開始する際に、処方されたまたは違法なベンゾジアゼピンまたは他の中枢神経抑制剤の使用を管理するための戦略を開発する。
- 可能であれば、ベンゾジアゼピンまたはCNS抑制剤を漸減して中止します。
- 患者が不安や不眠症のために処方されたベンゾジアゼピンまたは他の中枢神経系抑制剤を服用しているかどうかの診断を確認し、これらの状態に対する他の治療オプションを検討します。
- 患者がMAT薬を無期限に必要とする可能性があり、患者が恩恵を受け、その使用が意図された治療目標に寄与する限り、それらの使用を継続する必要があることを認識します。
- 他の処方者が患者のブプレノルフィンまたはメタドン治療を認識していることを確認するためのケアの調整。
- 尿や血液のスクリーニングを含む、違法薬物使用の監視。

MAT薬を服用している患者は、処方されたとおりにこれらの薬を服用し続ける必要があります。最初に医療専門家に相談せずに、他の処方薬の服用をやめないでください。新しい薬を始める前に、あなたがMATを服用していることをあなたの医療専門家に伝えてください。処方されていないベンゾジアゼピンまたは他の鎮静剤（表2.ベンゾジアゼピンおよび他の中枢神経抑制剤のリストを参照）を服用したり、MATを服用するときにアルコールを使用したりしないでください。併用すると、過剰摂取や死亡などの危害の可能性が高まります。

2016年8月に、オピオイドを含む鎮痛薬または咳止め薬とベンゾジアゼピンまたは他の中枢神経系抑制剤の併用について、[Drug Safety Communication](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or)の警告を発しました。
([/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or))当時、ベンゾジアゼピンまたは他の中枢神経系抑制剤とMAT薬の併用に関するエビデンスを引き続き評価すると述べました。

公開された研究³および他の薬物使用データのその後のレビューは、ブプレノルフィンとベンゾジアゼピンが同じ患者に、しばしば同じ処方者によって頻繁に処方され、これらの薬物は通常同じ薬局によって調剤されることを示しました。スウェーデンの疫学研究によると、ベンゾジアゼピンまたは不眠症治療薬などの他の中枢神経抑制剤と一緒にMATを投与すると、死亡のリスクが高まるようです。⁴この情報に基づいて、メタドン製品については、ベンゾジアゼピンおよび他の中枢神経抑制剤との相互作用に関する情報が、呼吸の遅延または困難および死亡のリスクに関する既存の*Boxed Warning*に追加されます。警告と注意事項に拡張ガイダンスが追加されますCNS抑制剤も服用しているオピオイド治療プログラム（OTP）でメタドン治療を受けている患者を管理する方法に関するセクション。ブプレノルフィン製品については、警告と注意のセクションの既存の声明が拡張および改訂され、CNS抑制剤も服用しているブプレノルフィン治療中の患者の管理に関するより詳細なガイダンスが提供されます。

ページ下部の「FDAに連絡」ボックスの情報を使用して、ブプレノルフィン、メタドン、またはその他の医薬品に関連する副作用をFDAMedWatchプログラムに報告するよう患者および医療専門家に要請します。

表1.ブプレノルフィンおよびメタドンMAT薬のリスト

一般名	ブランド名)
ブプレノルフィン	Subutex、プロブプレノルフィン
ブプレノルフィン/ナロキソン	ブプレノルフィン、スポクソン、ズブソルブ
メタドン	ディスクレット、ドロフィン、メタドース

Table 2. List of Benzodiazepines and Other CNS Depressants*

Generic Name	Brand Name(s)
Benzodiazepines	
alprazolam	Xanax, Xanax XR
chlordiazepoxide	Librium, Librax
clobazam	Onfi
clonazepam	Klonopin
clorazepate	Gen-Xene, Tranxene
diazepam	Diastat, Diastat Acudial, Valium
estazolam	No brand name currently marketed
flurazepam	No brand name currently marketed

上 0

lorazepam	Ativan
oxazepam	No brand name currently marketed
quazepam	Doral
temazepam	Restoril
triazolam	Halcion
Other Sleep (Non-Benzodiazepine Hypnotic) Drugs and Tranquilizers	
butabarbital sodium	Butisol
eszopiclone	Lunesta
pentobarbital	Nembutal
ramelteon	Rozerem
secobarbital sodium	Seconal sodium
suvorexant	Belsomra
zaleplon	Sonata
zolpidem	Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist
Muscle Relaxants	
baclofen	Gablofen, Lioresal
carisoprodol	Soma, Soma Compound, Soma Compound w/ codeine
chlorzoxazone	No brand name currently marketed
cyclobenzaprine	Amrix
dantrolene	Dantrium, Revonto, Ryanodex
metaxalone	Skelaxin
methocarbamol	Robaxin, Robaxin-750
orphenadrine	No brand name currently marketed
tizanidine	Zanaflex
Antipsychotics	
aripiprazole	Abilify, Abilify Maintena, Aristada
asenapine	Saphris
cariprazine	Vraylar

chlorpromazine	No brand name currently marketed
clozapine	Clozaril, Fazaclo ODT, Versacloz
fluphenazine	No brand name currently marketed
haloperidol	Haldol
iloperidone	Fanapt
loxapine	Adasuve
lurasidone	Latuda
molindone	No brand name currently marketed
olanzapine	Symbyax, Zyprexa, Zyprexa Relprevv, Zyprexa Zydis
paliperidone	Invega, Invega Sustenna, Invega Trinza
perphenazine	No brand name currently marketed
pimavanserin	Nuplazid
quetiapine	Seroquel, Seroquel XR
risperidone	Risperdal, Risperdal Consta
thioridazine	No brand name currently marketed
thiothixene	Navane
trifluoperazine	No brand name currently marketed
ziprasidone	Geodon

*This is not a comprehensive list.

Facts about Buprenorphine and Methadone

- Medicines containing buprenorphine or methadone as the active ingredient are FDA-approved to treat opioid addiction and dependency. These medicines are called medication-assisted treatment (MAT), and they are often used along with counseling and behavioral therapies to treat opioid addiction.
- Patients may require treatment with MAT medicines indefinitely.
- MAT medicines have been shown to be effective in reducing the negative health effects and deaths associated with opioid addiction and dependency.¹ Patients receiving MAT cut their risk of death from all causes in half.



- Buprenorphine and methadone relieve the withdrawal symptoms and psychological cravings experienced by patients addicted to opioids.⁵
- Methadone to treat opioid addiction is dispensed only at specially licensed treatment centers.
- Methadone is marketed under the brand names Diskets, Dolophine, and Methadose, and also as generics. Methadone is available as a tablet, liquid, and wafer.
- A physician must complete training in order to be qualified to prescribe or dispense buprenorphine to treat addiction.⁶ Buprenorphine is dispensed by retail pharmacies and sometimes at opioid treatment centers.
- Buprenorphine, either alone or in combination with other medicines, is marketed under the brand names Bunavail, Probuphine, Suboxone, and Zubsolv, and also as generics. Buprenorphine is available as a tablet dissolved under the tongue, as a film dissolved under the tongue, as a film dissolved on the inside of the cheek, and as an implant inserted into the upper arm.
- Common side effects of buprenorphine and methadone include nausea, vomiting, constipation, muscle aches and cramps, and sleep problems.

Additional Information for Patients

- If you are taking buprenorphine or methadone to treat opioid addiction or dependence (referred to as medication-assisted treatment or MAT), take care when combining these drugs with benzodiazepines or other sedatives to treat anxiety or insomnia. Taking both of these types of medicines can result in serious side effects, including overdose and death. These serious side effects result because buprenorphine, methadone, and benzodiazepines all impact (depress) the central nervous system (CNS). The CNS controls most of the functions of the body, including breathing.
- Combining the MAT medications buprenorphine or methadone with alcohol, or other prescription or illicit opioids such as heroin also increases these serious side effects.
- It is important to continue taking your buprenorphine or methadone as prescribed. Do not stop without first talking with your health care professional. Also do not stop or start any prescribed medicines without first talking to your health care professional.
- Always inform all your health care professionals about all the drugs you are taking, including prescription and over-the-counter (OTC) medicines, and other substances such as alcohol. It is helpful to keep a list of all your current medicines in your wallet or another location where the list is easily retrieved. You can fill out [▲] and print a copy of My Medicine Record (</media/73856/download>). _{上()}

- It is important to [lock up your medicines \(/consumers/consumer-updates/lock-it-medicine-safety-your-home\)](/consumers/consumer-updates/lock-it-medicine-safety-your-home) and to [dispose \(/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know\)](/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know) of them properly to keep them from being taken accidentally by children or falling into the wrong hands.
- Talk to your health care professional if you have any questions or concerns about buprenorphine, methadone, or other medicines you are taking.
- Read the patient [Medication Guide \(/drugs/drug-safety-and-availability/medication-guides\)](/drugs/drug-safety-and-availability/medication-guides) or patient information leaflet that comes with your filled prescription(s).
- Report side effects from buprenorphine, methadone, or other medicines to the FDA MedWatch program, using the information in the "Contact FDA" box at the bottom of this page.

Additional Information for Health Care Professionals

- The medication assisted treatment (MAT) drugs for opioid use disorder buprenorphine or methadone should not be categorically denied to patients taking benzodiazepines or other central nervous system (CNS) depressants.
- Although concomitant use of buprenorphine or methadone with benzodiazepines or other CNS depressants increases the risk of adverse reactions, including overdose and death, creating barriers to MAT can pose an even greater risk of morbidity and mortality due to the opioid use disorder.
- As a routine part of orientation to buprenorphine or methadone treatment, educate patients about the risks of concomitant use of benzodiazepines, sedatives, other prescribed opioid analgesics, alcohol, and illicit drugs.
- Develop strategies to manage use of prescribed or illicit benzodiazepines or other CNS depressants at initiation of buprenorphine or methadone treatment, or if it emerges as a concern during treatment. Adjustments to induction procedures and additional monitoring may be required.
- Current evidence does not support dose limitations or arbitrary caps of buprenorphine or methadone as a strategy to address benzodiazepine or other CNS depressant use in MAT-treated patients. However, if a patient is sedated at the time of buprenorphine or methadone dosing, a health care professional should evaluate the cause of sedation. Omitting or decreasing the dose of buprenorphine or methadone may be appropriate.
- Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use with MAT medicines. In some cases, monitoring at a higher level of care for tapering may be appropriate. In others, gradually tapering off a



prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose is appropriate.

- For patients receiving buprenorphine or methadone treatment, benzodiazepines are not the treatment of choice for anxiety or insomnia. Before co-prescribing benzodiazepines, ensure that patients are appropriately diagnosed and consider other medicines and nonpharmacologic treatments to address anxiety or insomnia.
- Recognize that patients may require MAT medications indefinitely, and their use should continue for as long as patients are benefiting and their use contributes to the intended treatment goals.
- Ensure that other health care professionals prescribing benzodiazepines or other CNS depressants are aware of the patient's methadone or buprenorphine treatment and coordinate care to minimize the risks associated with concomitant use. Take measures to confirm that patients are taking their medicines as prescribed and are not supplementing with illicit drugs. Toxicology screening should test for use of prescribed and illicit benzodiazepines or other CNS depressants.
- Report adverse events involving buprenorphine, methadone, or other medicines to the FDA MedWatch program, using the information in the "Contact FDA" box at the bottom of this page.

Data Summary

We conducted a drug utilization analysis of concomitant use of benzodiazepines with buprenorphine products being used for medication-assisted treatment (MAT), using the Prescription Behavior Surveillance System's (PBSS) data from 1/1/2013 to 12/31/2013. The PBSS includes de-identified, longitudinal data from eight participating state prescription drug monitoring programs: California, Ohio, Louisiana, Kentucky, West Virginia, Idaho, Maine, and Delaware.

Of 190,907 patients prescribed at least 7 consecutive days of buprenorphine therapy, 17.7 percent had at least one overlapping benzodiazepine prescription period of 7 or more days, and another 2.5 percent had at least one overlapping prescription period of less than 7 days. The median length of overlap in therapy across the eight states ranged from 29 to 41 days. The overlapping benzodiazepine and buprenorphine treatments were commonly prescribed by the same prescriber (ranging from 33.1 percent to 65.2 percent across the eight states) and dispensed by the same pharmacy (from 71.5 percent to 93.3 percent). PBSS data capture prescriptions filled for any payment source (e.g., cash, public insurance); however, prescriptions filled outside of the participating PBSS states may not have been captured, resulting in an underestimate of the number of patients who had concomitant buprenorphine and benzodiazepine prescriptions.



We also reviewed the published medical literature. Using prescription data from the Veterans Health Administration for fiscal year 2010, Park et al.³ noted that patients receiving MAT (n=5,409 for methadone; n=5,690 for buprenorphine) were commonly dispensed a benzodiazepine prescription. The median percent of patients who received concomitant methadone or buprenorphine prescriptions was 13.3 percent and 20.2 percent across multiple U.S. regions, respectively. These results from the Veterans Health Administration may not be generalizable to the entire U.S. population, but the finding of frequent overlapping prescriptions for benzodiazepines and buprenorphine was similar to findings from PBSS 2013 data described above.

Abrahamsson et al.⁴ analyzed data from a nationwide cohort of Swedish residents 18-50 years old who were dispensed methadone- or buprenorphine-based MAT between July 1, 2005 and December 31, 2012. Within the cohort of patients prescribed MAT, the authors compared the risk of fatal overdose, non-overdose-related mortality, and all-cause mortality during therapy episodes of prescribed CNS depressants to periods of time without CNS depressant therapy. CNS depressants included benzodiazepines (diazepam, oxazepam, lorazepam, alprazolam, nitrazepam, flunitrazepam, triazolam, midazolam, and clonazepam) and three non-benzodiazepine hypnotic drugs (zopiclone, zolpidem, and zaleplon). Of 4,501 patients in the MAT cohort, 32.4 percent filled a prescription for a benzodiazepine and 40.8 percent filled a prescription for one of three non-benzodiazepine hypnotic drugs. During periods of cotreatment with MAT and benzodiazepines, there was an elevated risk of non-overdose-related and all-cause mortality, although the associations were not considered statistically significant (Table 3). During periods of cotreatment with MAT and the non-benzodiazepine hypnotic drugs, there was an elevated risk of fatal overdose, non-overdose mortality, and all-cause mortality, but the associations were considered statistically significant only for fatal overdose and all-cause mortality. The hazard ratios for the non-benzodiazepine hypnotic drugs and benzodiazepines are not directly comparable because the authors did not adjust for the indication for use of these drugs. The authors estimated periods of active MAT based on prescription fill date and assumptions about how long MAT typically lasts, so periods of active MAT during follow-up may have been misclassified. Periods of active MAT may have also been missed if patients in the cohort received in-clinic MAT during follow-up. In addition, while the authors attempted to adjust for time periods when patients were using more than one concomitant CNS depressant, it is not clear whether the adjustment was sufficient to isolate the effects of a single CNS depressant when used concomitantly with MAT. Further, the authors' adjustments for sex, age, and time-dependent variables representing previous nonfatal overdose, psychiatric inpatient treatment, and suicide attempt, may not have been sufficient to control for the greater severity of comorbid psychiatric conditions likely during periods of concomitant use of CNS depressant drugs. Other potential confounders, including socioeconomic status, were not available in this data source.

Table 3. Risk of Death Associated with Periods of Concomitant Therapy with MAT and Benzodiazepines or Non-benzodiazepine Hypnotic Drugs in Sweden, July 2005-December 2012*

	Adjusted Hazard Ratio (95% Confidence Interval)		
	Overdose Mortality	Non-overdose Mortality	All-cause Mortality
Benzodiazepine Treatment	1.05 (0.51-2.15)	1.74 (1.00-3.01)	1.44 (0.93-2.23)
Non-benzodiazepine Hypnotic Drug Treatment	2.34 (1.37-3.99)	1.25 (0.71-2.20)	1.66 (1.12-2.45)

*The table is based on the paper by Abrahamsson et al.⁴ Benzodiazepines included in the study were diazepam, oxazepam, lorazepam, alprazolam, nitrazepam, flunitrazepam, triazolam, midazolam, and clonazepam. The non-benzodiazepine hypnotic drugs included in the study were zopiclone, zolpidem, and zaleplon.

A study by Warner et al.⁷ examined trends in drug overdose deaths from 2010 through 2014 using data from the National Vital Statistics System, which aggregates nationwide death certificate data. In 2014, 3,495 drug overdose deaths involved methadone, and other CNS depressant drugs were frequently involved in those deaths (Table 4). The benzodiazepines alprazolam and diazepam were the first and fifth most frequently involved concomitant drugs.

New FDA analyses using the same data source found 322 drug overdose deaths in 2014 that involved buprenorphine. Concomitant use of CNS depressant drugs was also frequently observed in deaths involving buprenorphine. Alprazolam, clonazepam, and diazepam were the most frequently involved concomitant drugs at death. Although the absolute number of methadone-involved deaths in 2014 was ten times the number of deaths involving buprenorphine, the data source did not have information to adjust for confounding or differences in drug utilization between methadone and buprenorphine. Therefore, we could not assess whether the risk of overdose death with concomitant CNS depressant drugs differed between methadone and buprenorphine. A limitation is that the quality of data extracted from death certificates depends on the level of detail provided by medical certifiers, which can vary by jurisdictions and over time. We also do not know whether the drugs were being used to treat pain or opioid use disorder, just that they were involved in the death.

Table 4: Most Frequent Concomitant Drugs for Drug Overdose Deaths Involving Selected Opioids: United States, 2014

Referent Drug	Number of Deaths Involving Referent	Number (%) Deaths Involving Both Referent Drug and Concomitant Drug

	Drug	Most Frequent Drug	Second Frequent Drug	Third Frequent Drug	Fourth Frequent Drug	Fifth Frequent Drug
buprenorphine	322	alprazolam 106 (32.9%)	clonazepam 56 (17.4%)	diazepam 36 (11.2%)	heroin 36 (11.2%)	fentanyl 32 (9.9%)
methadone	3,495	alprazolam 634 (18.1%)	oxycodone 352 (10.1%)	cocaine 337 (9.6%)	heroin 314 (9%)	diazepam 232 (6.6%)

Selected results using National Center for Health Statistics (NCHS), National Vital Statistics System. Mortality files linked with death certificate literal text, constructed for analysis on October 6, 2016.

References

1. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction* 2008;103:462-8.
2. Substance Abuse and Mental Health Services Administration. Medication-Assisted Treatment for Opioid Addiction: Facts for Family and Friends. Published 2009; revised 2011. Accessed June 27, 2017.
3. Park TW, Bohnert AS, Austin KL, Saitz R, Pizer SD. Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy. *Psychiatr Serv* 2014;65:4.
4. Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. *Drug Alcohol Depend* 2017;174:58-64.
5. Substance Abuse and Mental Health Services Administration. Medication and Counseling Treatment. <https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat> (<https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat>). Last updated September 28, 2015. Accessed June 30, 2017.
6. Substance Abuse and Mental Health Services Administration. Buprenorphine Training for Physicians. <https://www.samhsa.gov/medication-assisted-treatment/find-buprenorphine-waiver-training> (<https://www.samhsa.gov/medication-assisted-treatment/find-buprenorphine-waiver-training>). Last updated July 7, 2017. Accessed July 19, 2017.
7. Warner M, Trinidad J, Bastian B, Minino A, Hedegaard H. Drugs most frequently involved in drug overdose deaths: United States 2010-2014. *National Vital*



上 ()

Statistics Reports; vol 65 no 10. Hyattsville, MD: National Center for Health Statistics. 2016.

[en Español \(/drugs/drug-safety-and-availability/la-fda-insta-tener-precaucion-al-denegar-medicamentos-para-la-adiccion-opioides-pacientes-que-toman\)](#)

[Drug Safety Communication \(/media/127688/download\)](#) (PDF - 100KB)

関連情報

- [オピオイド薬 \(/drugs/information-drug-class/opioid-medications\)](#)
- [投薬とカウンセリング治療 \(https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat\)](https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat)
- [FDAの医薬品審査プロセス：医薬品が安全で効果的であることを確認する \(/drugs/information-consumers-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective\)](#)
- [考え抜く：医薬品の利点とリスクの管理 \(/drugs/information-consumers-drugs/think-it-through-managing-benefits-and-risks-medicines\)](#)